Clinical Trial Update: Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating bevacizumab with the mFOLFOXIRI regimen as first-line therapy for unresectable metastatic colorectal cancer; recruitment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• MFOLFOXIRI

Snippet

Sponsor: Yanhong Deng | Conditions: Colorectal Cancer | Phase 3 | Status: RECRUITING